What nephrologists need to know about gadolinium
暂无分享,去创建一个
[1] H. Thomsen,et al. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.
[2] John Gosbee,et al. ACR guidance document for safe MR practices: 2007. , 2007, AJR. American journal of roentgenology.
[3] G. Kost,et al. Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value. , 2004, Archives of pathology & laboratory medicine.
[4] Sophie Laurent,et al. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. , 2006, Contrast media & molecular imaging.
[5] J. Voorhees,et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. , 2004, Archives of dermatology.
[6] R. Dolan,et al. MS-325: albumin-targeted contrast agent for MR angiography. , 1998, Radiology.
[7] M. Lucia,et al. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis , 2007, Nature Clinical Practice Nephrology.
[8] J. Wittenberg,et al. Gd-DOTA: characterization of a new paramagnetic complex. , 1988, Radiology.
[9] W. Gibby,et al. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. , 1996, Investigative radiology.
[10] S. Jimenez,et al. Involvement of skeletal muscle in dialysis‐associated systemic fibrosis (nephrogenic fibrosing dermopathy) , 2004, Muscle & nerve.
[11] L. Skov,et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] T. Kumazaki,et al. Safety of gadolinium contrast agent in hemodialysis patients. , 2001, Acta radiologica.
[13] W. Ting,et al. Nephrogenic fibrosing dermopathy with systemic involvement. , 2003, Archives of dermatology.
[14] R. Prayson,et al. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. , 2006, Archives of pathology & laboratory medicine.
[15] S. Nehlsen-Cannarella,et al. Nephrogenic Fibrosing Dermopathy After Liver Transplantation Successfully Treated With Plasmapheresis , 2003, The American Journal of dermatopathology.
[16] M. Tweedle,et al. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.
[17] Yoshiaki Tanaka,et al. Dialyzability of gadodiamide in hemodialysis patients , 2006, Radiation Medicine.
[18] G. R. Stevens,et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function , 1999, Journal of magnetic resonance imaging : JMRI.
[19] H. Thomsen,et al. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? , 2007, Acta radiologica.
[20] Lone Skov,et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.
[21] K. Chung,et al. Nephrogenic fibrosing dermopathy: response to high‐dose intravenous immunoglobulin , 2004, The British journal of dermatology.
[22] P. Leboit,et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.
[23] S. Cowper. Nephrogenic fibrosing dermopathy: the first 6 years , 2003, Current opinion in rheumatology.
[24] C. Ayers,et al. Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO2-enhanced renal angiography for diagnosis and percutaneous treatment. , 1999, Radiology.
[25] K. Keven,et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[26] R. Swartz,et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. , 2003, The American journal of medicine.
[27] V. Runge,et al. Nephrogenic Systemic Fibrosis: A Review of 6 Cases Temporally Related to Gadodiamide Injection (Omniscan) , 2007, Investigative radiology.
[28] J. Kern,et al. Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. , 2000, Journal of vascular and interventional radiology : JVIR.
[29] M. Bellin,et al. Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. , 1992, Magnetic resonance imaging.
[30] L. Truong,et al. Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. , 2009, Archives of pathology & laboratory medicine.
[31] R. Elenitsas,et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema , 2005, Journal of cutaneous pathology.
[32] C. Cortese,et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[33] M. Taupitz,et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.
[34] Teut Risler,et al. Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[35] H. Thomsen,et al. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). , 1999, European radiology.
[36] T. Sancak,et al. Gadodiamide as an Alternative Contrast Agent in Intravenous Digital Subtraction Angiography and Interventional Procedures of the Upper Extremity Veins , 2002, CardioVascular and Interventional Radiology.
[37] S. Cowper,et al. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[38] F. Nestle,et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis , 2005, The British journal of dermatology.
[39] E. Kanal,et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. , 2007, Radiology.
[40] F. Mendoza,et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. , 2006, Seminars in arthritis and rheumatism.
[41] R. Fennell,et al. Nephrogenic fibrosing dermopathy in pediatric patients , 2004, Pediatric Nephrology.
[42] W. Cacheris,et al. The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.
[43] T. Sauerbruch,et al. MDRD Equations for Estimation of GFR in Renal Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[44] A. Spinazzi,et al. Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.
[45] Y. Araki,et al. Permeability of gadolinium-DTPA through two types of hemodialysis membrane. , 1998, Investigative radiology.
[46] B. Thiers. Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned , 2008 .
[47] L. V. Rao,et al. Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. , 2004, American journal of clinical pathology.
[48] J. Frisoli,et al. Nephrotoxicity of high‐dose gadolinium compared with iodinated contrast , 1996, Journal of magnetic resonance imaging : JMRI.
[49] J. Zic,et al. Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.
[50] F. S. Pereles,et al. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. , 2003, Journal of vascular surgery.
[51] M. Port,et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. , 1999, Journal of pharmaceutical and biomedical analysis.
[52] K. Higashino,et al. Permeability of iodinated and MR contrast media through two types of hemodialysis membrane. , 1999, European journal of radiology.
[53] Henrik S. Thomsen,et al. Gadolinium-based contrast media may be nephrotoxic even at approved doses , 2004, European Radiology.
[54] P. Goffette,et al. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography , 1999, European Radiology.
[55] A. Colombo,et al. Gadolinium‐based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[56] K Bensel,et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[57] S. Nedorost,et al. A variant of nephrogenic fibrosing dermopathy with osteoclast‐like giant cells: a syndrome of dysregulated matrix remodeling? , 2004, Journal of cutaneous pathology.
[58] J. Gerberding,et al. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006. , 2007, MMWR. Morbidity and mortality weekly report.
[59] D. Siegel,et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. , 2006, Journal of the American Academy of Dermatology.
[60] P. Choyke,et al. Clearance of gadolinium chelates by hemodialysis: An in vitro study , 1995, Journal of magnetic resonance imaging : JMRI.
[61] M. Port,et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.
[62] M. Edward,et al. Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum , 2007, The British journal of dermatology.
[63] J. Callen,et al. Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis , 2006, International journal of dermatology.
[64] M. Tweedle,et al. Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.
[65] P. Normann,et al. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. , 1995, Scandinavian journal of clinical and laboratory investigation.
[66] J. Caridi,et al. Spurious hypocalcemia after gadodiamide-enhanced magnetic resonance imaging: a case report and review of the literature. , 2006, Reviews in urology.
[67] N. Rofsky,et al. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. , 1991, Radiology.
[68] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[69] J. Kaufman,et al. Gadolinium-based contrast agents as an alternative at vena cavography in patients with renal insufficiency--early experience. , 1999, Radiology.
[70] H. P. Kang,et al. Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method. , 2004, Clinical chemistry.
[71] A. García‐Díez,et al. Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy , 2005, Journal of cutaneous pathology.
[72] K. Kent,et al. Gadodiamide administration causes spurious hypocalcemia. , 2003, Radiology.
[73] A. V. Moore. Commentary on “ACR Guidance Document for Safe MR Practices: 2007” , 2007 .
[74] G. Saab,et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[75] S. Cowper,et al. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[76] L. Schad,et al. Elimination of gadolinium-DTPA by peritoneal dialysis. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[77] T. Balzer,et al. Interference of Gadolinium-Containing Contrast-Enhancing Agents With Colorimetric Calcium Laboratory Testing , 2005, Investigative radiology.
[78] J. Caillé,et al. Gadolinium as a contrast agent for NMR. , 1983, AJNR. American journal of neuroradiology.
[79] H. Thomsen,et al. Gadolinium-containing contrast media for radiographic examinations: a position paper , 2002, European Radiology.
[80] D. Cohen,et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). , 2003, Journal of the American Academy of Dermatology.
[81] S. Swan,et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. , 1999, Investigative radiology.
[82] J. Barkun,et al. Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients. , 2004, Transplantation.
[83] M. Jarmulowicz,et al. Scleromyxoedema‐like changes in four renal dialysis patients , 2003, The British journal of dermatology.
[84] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[85] S. Jimenez,et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.
[86] S. Cowper,et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.
[87] N. Liégeois,et al. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. , 2003, Journal of the American Academy of Dermatology.
[88] Ulrich Linsenmaier,et al. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[89] A. Djamali,et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.
[90] W. Gibby,et al. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy , 2004, Investigative radiology.
[91] G. Krestin,et al. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. , 1991, Investigative radiology.
[92] T. Kumazaki,et al. Effect of the surface potential of the hemodialysis membrane and the electrical charge of the gadolinium contrast medium on dialyzability. , 2003, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.